ADC Therapeutics SA expected to post a loss of 46 cents a share - Earnings Preview

ADC Therapeutics SA

04/08/2023 12:27

* ADC Therapeutics SA  ADCT.N   ADCT.K  is expected to show
a rise
in quarterly revenue when it reports  results on August 8. 
    * The Epalinges Vaud-based  company is expected to report  a
140.3% increase in revenue to $41.555 million from $17.29
million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ADC Therapeutics SA
is
for a loss of 46 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $8.5​, above​ its last closing price of $1.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.76       -0.67      -0.74     Missed  -10.4
 Dec. 31 2023  -0.21       -0.29      -0.30     Missed  -4.6
 Sep. 30 2022  -0.30       -0.35      -0.65     Missed  -84.2​
 Jun. 30 2022  -0.92       -0.91      -0.84     Beat    8.1
 ​​Mar.        -0.69       -0.70      -0.22     Beat    68.4
 31 2022                                                
 Dec. 31 2021  -0.86       -0.86      -0.45     Beat    47.5​
 Sep. 30 2021  -0.96       -0.92      -0.93     Missed  -1.4
 Jun. 30 2021  -0.87       -0.86      -0.96     Missed  -11.6
 This summary was machine generated August 4 at 11:26 GMT.  All
figures in US dollars  unless otherwise stated